Today, private biotechnology company Arvinas LLC announced a multi-year collaboration with Merck, which will focus on multiple disease targets, utilizing Arvinas’ novel technology platform. The companies have entered a strategic collaboration, in which Arvinas’ novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel …